{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:14:26Z","timestamp":1778282066465,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T00:00:00Z","timestamp":1458518400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s12325-016-0320-y","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T10:27:39Z","timestamp":1458556059000},"page":"670-683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exposure\u2013Response Relationship for Ombitasvir and Paritaprevir\/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study"],"prefix":"10.1007","volume":"33","author":[{"given":"Sathej","family":"Gopalakrishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Mensing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Redman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiuhong","family":"Zha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,21]]},"reference":[{"key":"320_CR1","unstructured":"World Health Organization (WHO). Hepatitis C\u2014Fact Sheet No 164. April 2014. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/ . Accessed 10 Mar 2016."},{"issue":"Suppl 1","key":"320_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jvh.12253","volume":"21","author":"GJ Dore","year":"2014","unstructured":"Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden (guest editors Mark Thursz, Gregory Dore and John Ward). J Viral Hepatol. 2014;21(Suppl 1):1\u20134.","journal-title":"J Viral Hepatol."},{"issue":"4 Pt 1","key":"320_CR3","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/jhep.2001.27831","volume":"34","author":"AJ Freeman","year":"2001","unstructured":"Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34(4 Pt 1):809\u201316.","journal-title":"Hepatology"},{"issue":"1","key":"320_CR4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000252782","volume":"53","author":"H Chung","year":"2010","unstructured":"Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50\u00a0years in Japan. Intervirol. 2010;53(1):39\u201343.","journal-title":"Intervirol."},{"issue":"9","key":"320_CR5","doi-asserted-by":"crossref","first-page":"e73615","DOI":"10.1371\/journal.pone.0073615","volume":"8","author":"S Wu","year":"2013","unstructured":"Wu S, Kanda T, Nakamoto S, Jiang X, Miyamura T, Nakatani SM, et al. Prevalence of hepatitis C virus subgenotypes\u00a01a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region. PLoS One. 2013;8(9):e73615.","journal-title":"PLoS One"},{"issue":"5","key":"320_CR6","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1021\/jm401398x","volume":"57","author":"DA DeGoey","year":"2014","unstructured":"DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014;57(5):2047\u201357.","journal-title":"J Med Chem"},{"key":"320_CR7","unstructured":"VIEKIRA PAK\u00ae (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [package insert]. North Chicago, IL; AbbVie Inc., 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/206619s010lbl.pdf . Accessed 01 Mar 2016."},{"key":"320_CR8","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep.27972","volume":"62","author":"H Kumada","year":"2015","unstructured":"Kumada H, Chayama K, Rodrigues L Jr, Suzuki F, Ikeda K, Toyoda H, et al. Randomized phase 3 trial of ombitasvir\/paritaprevir\/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62:1037\u201346.","journal-title":"Hepatology"},{"key":"320_CR9","unstructured":"Gopalakrishnan S, Polepally A, Mensing S, Menon R, Khatri A. Population pharmacokinetics of paritaprevir, ombitasvir and ritonavir in Japanese subjects with HCV genotype 1b infection [abstract 39]. In: Reviews in antiviral therapy & infectious diseases 2015;4:43\u201344. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington, DC, 26\u201328 May, 2015."},{"key":"320_CR10","unstructured":"R Core Team (2014). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http:\/\/www.R-project.org\/ . Accessed 10 Mar 2016."},{"issue":"12","key":"320_CR11","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","volume":"49","author":"P Peduzzi","year":"1996","unstructured":"Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373\u20139.","journal-title":"J Clin Epidemiol"},{"key":"320_CR12","volume-title":"Applied logistic regression","author":"DW Hosmer","year":"2004","unstructured":"Hosmer DW, Lemeshow S. Applied logistic regression.\u00a02nd ed. New York: Wiley; 2004.","edition":"2"},{"key":"320_CR13","unstructured":"NORVASC\u00ae (amlodipine besylate tablets) [package insert]. New York, NY; Pfizer Labs, a division of Pfizer Inc., 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/019787s059lbl.pdf . Accessed 11 Nov 2015."},{"issue":"1","key":"320_CR14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2015.01.026","volume":"63","author":"RM Menon","year":"2015","unstructured":"Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir\/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63(1):20\u20139.","journal-title":"J Hepatol"},{"issue":"3","key":"320_CR15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40262-015-0317-8","volume":"55","author":"PS Badri","year":"2016","unstructured":"Badri PS, King JR, Polepally AR, McGovern BH, Dutta S, Menon RM. Dosing recommendations for concomitant medications during 3D anti-HCV therapy. Clin Pharmacokinet. 2016;55(3):275\u201395.","journal-title":"Clin Pharmacokinet"},{"key":"320_CR16","unstructured":"OLYSIO\u00ae (simeprevir capsules) [package insert]. Titusville, NJ; Janssen Therapeutics, Division of Janssen Products, LP, 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/205123s005lbl.pdf . Accessed 11 Nov 2015."},{"key":"320_CR17","author":"RM Menon","year":"2015","unstructured":"Menon RM, Klein CE, Podsadecki TJ, Chiu YL, Dutta S, Awni WM. Pharmacokinetics and tolerability of paritaprevir, a direct-acting antiviral agent for HCV treatment, with and without ritonavir in healthy volunteers. Br J Clin Pharmacol. 2015. doi: 10.1111\/bcp.12873 .","journal-title":"Br J Clin Pharmacol"},{"key":"320_CR18","unstructured":"Bow DAJ, Liu J, Kavetskaia O, Menon R, de Morais SM, Nijsen M. 2014. A mechanistic non-clinical assessment of drug-drug interactions (metabolism and transporters) with the hepatitis C virus (HCV) regimen: ABT-450\/r, ombitasvir and dasabuvir, abstr AASLD\/EASL Special Conference on Hepatitis C, New York, NY, October 3\u20135, 2014."},{"key":"320_CR19","unstructured":"Menon R, Badri P, Khatri A, Wang T, Bow S, Polepally A. 2014. ABT\u2013450\/ritonavir\u00a0+\u00a0ombitasvir\u00a0+\u00a0dasabuvir: drug interactions mediated by transporters, abstr 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington, DC, May 19\u201321, 2014."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0320-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-016-0320-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0320-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T03:56:08Z","timestamp":1559447768000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0320-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,21]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["320"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0320-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,21]]}}}